Real-life use of cetuximab as 1st-line treatment of metastatic colorectal cancer in France: evaluation of the conformity with SmPC and guidelines - results of the EREBUS cohort study

被引：0
|
作者：
Rouyer, M. [1 ]
Fourrier-Reglat, A. [2 ]
Mitry, E. [3 ]
Francois, E. [4 ]
Bignon, E. [1 ]
De Sagazan, A. Le Monies [1 ]
Jove, J. [1 ]
Moore, N. [2 ]
Noize, P. [1 ]
Smith, D. [1 ]
机构：
[1] Univ Bordeaux Segalen, CICP 0005, Bordeaux, France
[2] Univ Bordeaux Segalen, CHU Bordeaux, CICP 0005, Bordeaux, France
[3] Inst Curie, St Cloud, France
[4] Ctr Lacassagne, Nice, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
colorectal cancer; cetuximab; pharmacoepidemiology;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [1] Real-life use of cetuximab as 1st-line treatment of metastatic colorectal cancer in France: evaluation of the conformity with SmPC and guidelines - results of the EREBUS cohort study
    Rouyer, M.
    Fourrier-Reglat, A.
    Mitry, E.
    Francois, E.
    Bignon, E.
    de Sagazan, A. L. E. Monies
    Jove, J.
    Moore, N.
    Noize, P.
    Smith, D.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 25 - 25
  • [2] Survival outcomes and prognostic factors in real-life practice after treatment with cetuximab in 1st-line metastatic colorectal cancer in the EREBUS cohort
    Fourrier-Reglat, A.
    Rouyer, M.
    Noize, N.
    Bignon, E.
    Jove, J.
    Monnereau, A.
    Cunha, A. Sa
    Francois, E.
    Mitry, E.
    Smith, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S554 - S554
  • [3] Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.
    Smith, Denis
    Rouyer, Magali
    Mitry, Emmanuel
    Monnereau, Alain
    Cunha, Antonio Sa
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Noize, P.
    Moore, Nicholas
    Fourrier-Reglat, Annie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [4] Pattern of bevacizumab use in 1st-line therapy metastatic colorectal cancer (mCRC) in real-life practice: results of the ETNA cohort study
    Smith, D.
    Rouyer, M.
    Balestra, A.
    Jayles, D.
    Guimbaud, R.
    Michel, P.
    Bernard, O.
    Ravaud, A.
    Moore, N.
    Fourrier-Reglat, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 342 - 343
  • [5] Use of cetuximab in a real-life setting in France with respect to KRAS status: results of EREBUS cohort study
    Fourrier-Reglat, Annie
    Smith, Denis
    Rouyer, Magali
    Francois, Eric
    Mitry, Emmanuel
    Monnereau, Alain
    Sa-Cunha, Antonio
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Noize, Pernelle
    Moore, Nicholas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 334 - 334
  • [6] Use of Cetuximab (CTX) in 1st-Line Therapy of Metastatic Colorectal Cancer (mCRC): Patient Characteristics, Safety and Effectiveness in the EREBUS Cohort
    Fourrier-Reglat, Annie
    Smith, Denis
    Rouyer, Magali
    Francois, Eric
    Mitry, Emmanuel
    Monnereau, Alain
    Sa-Cunha, Antonio
    Bignon, Emmanuelle
    Le Monies, Alise
    Lassalle, Regis
    Noize, Pernelle
    Moore, Nicholas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 458 - 459
  • [7] Cetuximab with Irinotecan or Oxaliplatin for 1st-Line Metastatic Colorectal Cancer: Effectiveness in the EREBUS Cohort Compared to Pivotal Trials
    Noize, Pernelle
    Fourrier-Reglat, Annie
    Rouyer, Magali
    Grelaud, Angela
    Bignon, Emmanuelle
    de Sagazan, Alise Le Monies
    Lassalle, Regis
    Jove, Jeremy
    Monnereau, Alain
    Cunha, Antonio Sa
    Francois, Eric
    Mitry, Emmanuel
    Moore, Nicholas
    Smith, Denis
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 60 - 61
  • [8] USE OF CETUXIMAB (CTX) IN 1ST-LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC): PATIENT CHARACTERISTICS, SAFETY AND EFFECTIVENESS IN THE EREBUS COHORT
    Smith, D.
    Rouyer, M.
    Mitry, E.
    Francois, E.
    Monnereau, A.
    Sa-Cunha, A.
    Jove, J.
    Noize, P.
    Moore, N.
    Fourrier-Reglat, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 219 - 219
  • [9] Pattern of Bevacizumab (BV) Use in 1st-Line Therapy Metastatic Colorectal Cancer (mCRC) in Real-Life Practice: Results of the ETNA Cohort Study
    Fourrier-Reglat, A.
    Smith, D.
    Ravaud, A.
    Rouyer, M.
    Balestra, A.
    Jayles, D.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S112 - S112
  • [10] Effectiveness, safety and pattern of bevacizumab (BY) use in 1st-line therapy metastatic colorectal cancer (mCRC) in real-life practice: results of the ETNA cohort study
    Fourrier-Reglat, A.
    Smith, D.
    Ravaud, A.
    Rouyer, M.
    Balestra, A.
    Bernard, M. A.
    Moore, N.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 68 - 68
12345